188 related articles for article (PubMed ID: 16523797)
1. [Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].
Holleman F; Gerdes VE; de Vries JH; Hoekstra JB
Ned Tijdschr Geneeskd; 2006 Feb; 150(7):358-60. PubMed ID: 16523797
[TBL] [Abstract][Full Text] [Related]
2. [Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].
Veneman TF
Ned Tijdschr Geneeskd; 2006 Apr; 150(16):931-2; author reply 932-3. PubMed ID: 16686096
[No Abstract] [Full Text] [Related]
3. [Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].
Heine RJ
Ned Tijdschr Geneeskd; 2006 Apr; 150(16):930-1; author reply 932-3. PubMed ID: 16686095
[No Abstract] [Full Text] [Related]
4. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone.
Betteridge DJ
Fundam Clin Pharmacol; 2009 Dec; 23(6):675-9. PubMed ID: 19744248
[TBL] [Abstract][Full Text] [Related]
5. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
Dormandy JA; Charbonnel B; Eckland DJ; Erdmann E; Massi-Benedetti M; Moules IK; Skene AM; Tan MH; Lefèbvre PJ; Murray GD; Standl E; Wilcox RG; Wilhelmsen L; Betteridge J; Birkeland K; Golay A; Heine RJ; Korányi L; Laakso M; Mokán M; Norkus A; Pirags V; Podar T; Scheen A; Scherbaum W; Schernthaner G; Schmitz O; Skrha J; Smith U; Taton J;
Lancet; 2005 Oct; 366(9493):1279-89. PubMed ID: 16214598
[TBL] [Abstract][Full Text] [Related]
6. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
Erdmann E; Dormandy JA; Charbonnel B; Massi-Benedetti M; Moules IK; Skene AM;
J Am Coll Cardiol; 2007 May; 49(17):1772-80. PubMed ID: 17466227
[TBL] [Abstract][Full Text] [Related]
7. Organ protection in the secondary prevention of type 2 diabetes.
Schernthaner G
Drugs Today (Barc); 2006 Dec; 42 Suppl C():17-23. PubMed ID: 17245477
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
Lincoff AM; Wolski K; Nicholls SJ; Nissen SE
JAMA; 2007 Sep; 298(10):1180-8. PubMed ID: 17848652
[TBL] [Abstract][Full Text] [Related]
9. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
[TBL] [Abstract][Full Text] [Related]
10. [Proactive study: secondary cardiovascular prevention with pioglitazione in type 2 diabetic patients].
Scheen AJ; Lefèbvre PJ
Rev Med Liege; 2005 Nov; 60(11):896-901. PubMed ID: 16402538
[TBL] [Abstract][Full Text] [Related]
11. [Are pioglitazone and fenofibrate effective for the prevention of cardiovascular disease in type 2 diabetes?].
Ruiz J
Rev Med Suisse; 2006 Jan; 2(48):116-8. PubMed ID: 16463795
[TBL] [Abstract][Full Text] [Related]
12. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
Wilcox R; Kupfer S; Erdmann E;
Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
[TBL] [Abstract][Full Text] [Related]
13. PROactive: time for a critical appraisal.
Betteridge DJ; DeFronzo RA; Chilton RJ
Eur Heart J; 2008 Apr; 29(8):969-83. PubMed ID: 18375395
[TBL] [Abstract][Full Text] [Related]
14. Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial.
Punthakee Z; Bosch J; Dagenais G; Diaz R; Holman R; Probstfield J; Ramachandran A; Riddle M; Rydén LE; Zinman B; Afzal R; Yusuf S; Gerstein H;
Diabetologia; 2012 Jan; 55(1):36-45. PubMed ID: 22038523
[TBL] [Abstract][Full Text] [Related]
15. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients.
Charbonnel B; Dormandy J; Erdmann E; Massi-Benedetti M; Skene A;
Diabetes Care; 2004 Jul; 27(7):1647-53. PubMed ID: 15220241
[TBL] [Abstract][Full Text] [Related]
16. Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14).
Spanheimer R; Betteridge DJ; Tan MH; Ferrannini E; Charbonnel B;
Am J Cardiol; 2009 Jul; 104(2):234-9. PubMed ID: 19576353
[TBL] [Abstract][Full Text] [Related]
17. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB
Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
[TBL] [Abstract][Full Text] [Related]
18. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
19. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
Krentz A
Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular risk and cardiometabolic protection: role of glitazones.
Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]